RU2008123406A - Способ мониторирования эффекта от лечения у больного раком пациента (варианты) и способ оценки состояния больного раком пациента - Google Patents
Способ мониторирования эффекта от лечения у больного раком пациента (варианты) и способ оценки состояния больного раком пациента Download PDFInfo
- Publication number
- RU2008123406A RU2008123406A RU2008123406/15A RU2008123406A RU2008123406A RU 2008123406 A RU2008123406 A RU 2008123406A RU 2008123406/15 A RU2008123406/15 A RU 2008123406/15A RU 2008123406 A RU2008123406 A RU 2008123406A RU 2008123406 A RU2008123406 A RU 2008123406A
- Authority
- RU
- Russia
- Prior art keywords
- patient
- cancer
- level
- sample
- ill
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 61
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 26
- 201000011510 cancer Diseases 0.000 title claims abstract 23
- 238000011282 treatment Methods 0.000 title claims abstract 8
- 230000000694 effects Effects 0.000 title claims abstract 7
- 238000012544 monitoring process Methods 0.000 title claims abstract 6
- 239000000523 sample Substances 0.000 claims abstract 29
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims abstract 26
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract 26
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract 26
- 239000011230 binding agent Substances 0.000 claims abstract 10
- 230000009870 specific binding Effects 0.000 claims abstract 10
- 239000011159 matrix material Substances 0.000 claims abstract 8
- 229920002477 rna polymer Polymers 0.000 claims abstract 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract 7
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims abstract 6
- 229960003787 sorafenib Drugs 0.000 claims abstract 6
- 210000001124 body fluid Anatomy 0.000 claims abstract 3
- 239000010839 body fluid Substances 0.000 claims abstract 3
- 238000000636 Northern blotting Methods 0.000 claims abstract 2
- 108091008605 VEGF receptors Proteins 0.000 claims abstract 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims abstract 2
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- 239000013068 control sample Substances 0.000 claims abstract 2
- 102000040430 polynucleotide Human genes 0.000 claims abstract 2
- 108091033319 polynucleotide Proteins 0.000 claims abstract 2
- 239000002157 polynucleotide Substances 0.000 claims abstract 2
- 238000010839 reverse transcription Methods 0.000 claims abstract 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims abstract 2
- 206010039491 Sarcoma Diseases 0.000 claims 9
- 208000032839 leukemia Diseases 0.000 claims 8
- 210000002381 plasma Anatomy 0.000 claims 8
- 239000012472 biological sample Substances 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 201000001441 melanoma Diseases 0.000 claims 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 206010003571 Astrocytoma Diseases 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 230000001850 reproductive effect Effects 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 208000030239 cerebral astrocytoma Diseases 0.000 claims 3
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims 3
- 208000030883 malignant astrocytoma Diseases 0.000 claims 3
- 210000002345 respiratory system Anatomy 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006143 Brain stem glioma Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 206010061252 Intraocular melanoma Diseases 0.000 claims 2
- 206010062038 Lip neoplasm Diseases 0.000 claims 2
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 claims 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000007641 Pinealoma Diseases 0.000 claims 2
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000005969 Uveal melanoma Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 210000004381 amniotic fluid Anatomy 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 201000005389 breast carcinoma in situ Diseases 0.000 claims 2
- 201000002143 bronchus adenoma Diseases 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000024207 chronic leukemia Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 210000001508 eye Anatomy 0.000 claims 2
- 208000024519 eye neoplasm Diseases 0.000 claims 2
- 210000000232 gallbladder Anatomy 0.000 claims 2
- 210000002768 hair cell Anatomy 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 230000002267 hypothalamic effect Effects 0.000 claims 2
- 238000011221 initial treatment Methods 0.000 claims 2
- 201000008893 intraocular retinoblastoma Diseases 0.000 claims 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000000244 kidney pelvis Anatomy 0.000 claims 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 2
- 201000006721 lip cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000011059 lobular neoplasia Diseases 0.000 claims 2
- 208000025036 lymphosarcoma Diseases 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 210000001989 nasopharynx Anatomy 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000008106 ocular cancer Diseases 0.000 claims 2
- 201000002575 ocular melanoma Diseases 0.000 claims 2
- 210000003300 oropharynx Anatomy 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000002990 parathyroid gland Anatomy 0.000 claims 2
- 210000003899 penis Anatomy 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000024724 pineal body neoplasm Diseases 0.000 claims 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 2
- 201000001514 prostate carcinoma Diseases 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 210000003079 salivary gland Anatomy 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 210000000582 semen Anatomy 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000004927 skin cell Anatomy 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 210000000626 ureter Anatomy 0.000 claims 2
- 210000003708 urethra Anatomy 0.000 claims 2
- 210000001635 urinary tract Anatomy 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 2
- 210000001215 vagina Anatomy 0.000 claims 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims 2
- 210000003905 vulva Anatomy 0.000 claims 2
- -1 4-pyridyl oxy Chemical group 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 238000003119 immunoblot Methods 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 claims 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73585405P | 2005-11-14 | 2005-11-14 | |
| US60/735,854 | 2005-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008123406A true RU2008123406A (ru) | 2009-12-27 |
Family
ID=37814675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008123406/15A RU2008123406A (ru) | 2005-11-14 | 2006-11-14 | Способ мониторирования эффекта от лечения у больного раком пациента (варианты) и способ оценки состояния больного раком пациента |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20070178494A1 (enExample) |
| EP (1) | EP1963849A2 (enExample) |
| JP (1) | JP2009515553A (enExample) |
| KR (1) | KR20080073745A (enExample) |
| CN (1) | CN101454668A (enExample) |
| AU (1) | AU2006315592A1 (enExample) |
| BR (1) | BRPI0618597A2 (enExample) |
| CA (1) | CA2629860A1 (enExample) |
| MX (1) | MX2008006239A (enExample) |
| RU (1) | RU2008123406A (enExample) |
| WO (1) | WO2007059094A2 (enExample) |
| ZA (1) | ZA200804509B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| PT1636585E (pt) | 2003-05-20 | 2008-03-27 | Bayer Pharmaceuticals Corp | Diarilureias com actividade inibidora de cinase |
| NZ544920A (en) | 2003-07-23 | 2009-11-27 | Bayer Healthcare Llc | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
| NZ561178A (en) | 2005-03-07 | 2010-11-26 | Bayer Schering Pharma Ag | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer |
| AU2006304764A1 (en) * | 2005-10-21 | 2007-04-26 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
| CA2628091A1 (en) * | 2005-11-02 | 2007-05-18 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
| US20100008910A1 (en) * | 2006-09-12 | 2010-01-14 | John Chant | Methods and compositions for the diagnosis and treatment of cancer |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| US20100311106A1 (en) * | 2008-01-25 | 2010-12-09 | Hartmann Lynn C | Quantitation of lobular involution for breast cancer risk prediction |
| GB0814722D0 (en) * | 2008-08-12 | 2008-09-17 | Ge Healthcare Ltd | Treatment monitoring |
| EP2156834A1 (en) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
| WO2010048304A2 (en) | 2008-10-21 | 2010-04-29 | Bayer Healthcare Llc | Identification of signature genes associated with hepatocellular carcinoma |
| WO2011042829A1 (en) * | 2009-10-07 | 2011-04-14 | Koninklijke Philips Electronics N.V. | Method of evaluating toxicity level of a patient undergoing a cancer treatment |
| CN102053150B (zh) * | 2009-10-30 | 2013-07-17 | 上海交通大学医学院附属瑞金医院 | 一种人成骨肉瘤干细胞相关抗原标记物及其应用 |
| BR112013001423A2 (pt) * | 2010-07-19 | 2016-05-24 | Hoffmann La Roche | método, método in vitro, uso e kit útil para realizar o método |
| US20130131136A1 (en) * | 2010-08-02 | 2013-05-23 | Nicolae Ghinea | Novel methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor |
| KR101437718B1 (ko) * | 2010-12-13 | 2014-09-11 | 사회복지법인 삼성생명공익재단 | 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법 |
| PL3141617T3 (pl) * | 2011-01-11 | 2019-04-30 | Assist Publique Hopitaux De Paris | Sposoby przewidywania wyniku w związku z nowotworem u pacjenta przez analizowanie ekspresji genów |
| WO2013173384A1 (en) * | 2012-05-16 | 2013-11-21 | Dale Wong | Method and system for sorting biological samples |
| EP2971101A2 (en) * | 2013-03-15 | 2016-01-20 | Janssen Pharmaceutica N.V. | Assay for predictive biomarkers |
| EP2989466B1 (en) * | 2013-04-25 | 2018-10-31 | CBS Bioscience, Co., Ltd | Analytical method for increasing susceptibility of molecular targeted therapy in hepatocellular carcinoma |
| RU2546035C1 (ru) * | 2014-04-15 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ прогнозирования развития метастазов у больных меланомой кожи |
| RU2643761C1 (ru) * | 2017-08-10 | 2018-02-05 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ расчета прогноза раннего прогрессирования меланомы кожи |
| WO2019074920A1 (en) * | 2017-10-10 | 2019-04-18 | Oncocyte Corporation | METHODS AND COMPOSITIONS FOR THE DETECTION AND DIAGNOSIS OF BREAST CANCER |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635421B1 (en) * | 1997-12-09 | 2003-10-21 | Children's Medical Center Corporation | Neuropilins and use thereof in methods for diagnosis and prognosis of cancer |
| US20030232400A1 (en) * | 2002-12-20 | 2003-12-18 | Susan Radka | Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome |
| WO2005009367A2 (en) * | 2003-07-17 | 2005-02-03 | Ambit Biosciences Corporation | Treatment of diseases with kinase inhibitors |
| CA2560269A1 (en) * | 2004-03-19 | 2005-09-29 | The Penn State Research Foundation | Combinatorial methods and compositions for treatment of melanoma |
-
2006
- 2006-11-14 JP JP2008541268A patent/JP2009515553A/ja active Pending
- 2006-11-14 AU AU2006315592A patent/AU2006315592A1/en not_active Abandoned
- 2006-11-14 WO PCT/US2006/044117 patent/WO2007059094A2/en not_active Ceased
- 2006-11-14 US US11/598,824 patent/US20070178494A1/en not_active Abandoned
- 2006-11-14 CA CA002629860A patent/CA2629860A1/en not_active Abandoned
- 2006-11-14 CN CNA2006800505936A patent/CN101454668A/zh active Pending
- 2006-11-14 BR BRPI0618597-5A patent/BRPI0618597A2/pt not_active IP Right Cessation
- 2006-11-14 MX MX2008006239A patent/MX2008006239A/es not_active Application Discontinuation
- 2006-11-14 RU RU2008123406/15A patent/RU2008123406A/ru not_active Application Discontinuation
- 2006-11-14 KR KR1020087014220A patent/KR20080073745A/ko not_active Withdrawn
- 2006-11-14 EP EP06837519A patent/EP1963849A2/en not_active Withdrawn
-
2008
- 2008-05-23 ZA ZA200804509A patent/ZA200804509B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200804509B (en) | 2009-05-27 |
| US20070178494A1 (en) | 2007-08-02 |
| AU2006315592A1 (en) | 2007-05-24 |
| EP1963849A2 (en) | 2008-09-03 |
| WO2007059094A3 (en) | 2008-01-24 |
| CN101454668A (zh) | 2009-06-10 |
| CA2629860A1 (en) | 2007-05-24 |
| WO2007059094A2 (en) | 2007-05-24 |
| JP2009515553A (ja) | 2009-04-16 |
| BRPI0618597A2 (pt) | 2011-09-06 |
| KR20080073745A (ko) | 2008-08-11 |
| MX2008006239A (es) | 2008-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008123406A (ru) | Способ мониторирования эффекта от лечения у больного раком пациента (варианты) и способ оценки состояния больного раком пациента | |
| Bekaii-Saab et al. | A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas | |
| Yano et al. | Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer | |
| Govindan et al. | Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B | |
| Kebebew et al. | A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer | |
| RU2017126701A (ru) | Способ детекции нуклеосом, содержащих нуклеотиды | |
| Goitein et al. | Mapping of ghrelin gene expression and cell distribution in the stomach of morbidly obese patients—a possible guide for efficient sleeve gastrectomy construction | |
| Liu et al. | Overexpression of lysine-specific demethylase 1 is associated with tumor progression and unfavorable prognosis in Chinese patients with endometrioid endometrial adenocarcinoma | |
| Coyne et al. | RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii | |
| KR101903838B1 (ko) | 유방암 관련 stk32c 유전자 및 이의 용도 | |
| Choi et al. | Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma | |
| Dolly et al. | Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy | |
| ES2436667B1 (es) | Suero biomarcador para diagnosticar el cáncer colorrectal | |
| Wu et al. | Molecular biology of inflammatory breast cancer: applications to diagnosis, prognosis, and therapy | |
| CN104321649A (zh) | 用于诊断阿扎胞苷耐药性的试验 | |
| Zhao et al. | Overexpression of long noncoding RNA E2F-mediated cell proliferation enhancing long noncoding RNA is involved in the development of chemoresistance of cancer cells to carboplatin in ovarian endometrioid adenocarcinoma | |
| Johns et al. | Diagnosis and staging of equine neoplasia | |
| EP2766499A1 (en) | Method for detection of g 15 as tumor marker in pancreatic cancer | |
| CN102724981A (zh) | 针对肝细胞癌症患者的化学疗法的治疗效果预测方法 | |
| RU2275636C1 (ru) | Способ прогнозирования рецидивов в мочевой пузырь у больных раком почечной лоханки и мочеточника после радикального хирургического лечения | |
| JP2008535491A5 (enExample) | ||
| US10316319B2 (en) | Composition for diagnosis of liver metastasis of colorectal cancer and the use thereof | |
| JP2022531319A (ja) | 癌の検出法 | |
| JP7742129B2 (ja) | 大動脈瘤の診断、治療剤、および、治療剤のスクリーニングのための新技術 | |
| RU2012100905A (ru) | Биомаркер er2 для гинекологического рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110722 |